{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:38:25Z","timestamp":1792157905223,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ijbiomac.2023.128618","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T02:36:27Z","timestamp":1702002987000},"page":"128618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"P2","title":["Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment"],"prefix":"10.1016","volume":"257","author":[{"given":"Yanyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longguang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2023.128618_bb0005","series-title":"Global, Regional, and Country-specific Lifetime Risks of Stroke","first-page":"2429","author":"Feigin","year":"1990"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.128618_bb0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/jcbfm.1984.22","article-title":"Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study","volume":"4","author":"Baron","year":"1984","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"7","key":"10.1016\/j.ijbiomac.2023.128618_bb0015","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.128618_bb0020","first-page":"425","article-title":"Intravenous thrombolysis for acute ischemic stroke, continuum: lifelong learning in neurology","volume":"29","author":"Grotta","year":"2023"},{"issue":"9834","key":"10.1016\/j.ijbiomac.2023.128618_bb0025","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial","volume":"379","author":"I.-C. Group","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.128618_bb0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa0800836","article-title":"Effect of pneumococcal conjugate vaccine on pneumococcal meningitis","volume":"360","author":"Hsu","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ijbiomac.2023.128618_bb0035","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199605233342114","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"334","author":"Koroshetz","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.128618_bb0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.014","article-title":"Low-dose tissue plasminogen activator in acute ischemic stroke: a systematic review and meta-analysis","volume":"27","author":"Cheng","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0045","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2147\/DDDT.S133759","article-title":"Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator","volume":"11","author":"Ong","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.128618_bb0050","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/01.STR.23.5.641","article-title":"Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset","volume":"23","author":"Haley","year":"1992","journal-title":"Stroke"},{"issue":"16","key":"10.1016\/j.ijbiomac.2023.128618_bb0055","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2174\/1389450120666190715102510","article-title":"Recognition of plasminogen activator inhibitor type 1 as the primary regulator of fibrinolysis","volume":"20","author":"Urano","year":"2019","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.128618_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0038-1648134","article-title":"Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction","volume":"65","author":"Sane","year":"1991","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.128618_bb0065","first-page":"171","article-title":"Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction","volume":"27","author":"Yamada","year":"1996","journal-title":"J. Cardiol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.128618_bb0070","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1161\/01.ATV.16.10.1277","article-title":"High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi","volume":"16","author":"Fay","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"06","key":"10.1016\/j.ijbiomac.2023.128618_bb0075","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1160\/TH04-02-0097","article-title":"Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator","volume":"91","author":"Ribo","year":"2004","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.128618_bb0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3988\/jcn.2005.1.2.142","article-title":"Plasma fibrinolysis inhibitor levels in acute stroke patients with thrombolysis failure","volume":"1","author":"Kim","year":"2005","journal-title":"J. Clin. Neurol."},{"issue":"43","key":"10.1016\/j.ijbiomac.2023.128618_bb0085","doi-asserted-by":"crossref","first-page":"25795","DOI":"10.1074\/jbc.M115.677567","article-title":"Crystal structure of the Michaelis complex between tissue-type plasminogen activator and plasminogen activators inhibitor-1","volume":"290","author":"Gong","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0090","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40263-015-0280-9","article-title":"Therapeutic potential of tenecteplase in the management of acute ischemic stroke","volume":"29","author":"Logallo","year":"2015","journal-title":"CNS Drugs"},{"issue":"01","key":"10.1016\/j.ijbiomac.2023.128618_bb0095","doi-asserted-by":"crossref","first-page":"077","DOI":"10.1055\/s-0038-1676518","article-title":"tPA point mutation at autolysis loop enhances resistance to PAI-1 inhibition and catalytic activity","volume":"119","author":"Peng","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122878","article-title":"A triple fusion tissue-type plasminogen activator (TriF-\u0394tPA) enhanced thrombolysis in carotid embolism-induced stroke model","volume":"637","author":"Xu","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"07","key":"10.1016\/j.ijbiomac.2023.128618_bb0105","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1160\/TH16-11-0891","article-title":"A long-acting PAI-1 inhibitor reduces thrombus formation","volume":"117","author":"Peng","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.128618_bb0110","first-page":"683","article-title":"Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis","volume":"20","author":"Jankun","year":"2007","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.128618_bb0115","doi-asserted-by":"crossref","first-page":"14151","DOI":"10.1038\/ncomms14151","article-title":"Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation","volume":"8","author":"Bowley","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105540","article-title":"Anti-thrombotic effects mediated by dihydromyricetin involve both platelet inhibition and endothelial protection","volume":"167","author":"Chen","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biomaterials.2017.03.012","article-title":"Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis","volume":"128","author":"Pawlowski","year":"2017","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.128618_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202102213","article-title":"A clot-homing near-infrared probe for in vivo imaging of murine thromboembolic models","volume":"11","author":"Chen","year":"2022","journal-title":"Adv. Healthc. Mater."},{"issue":"13","key":"10.1016\/j.ijbiomac.2023.128618_bb0135","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/WNR.0000000000001706","article-title":"Neurovascular protection of salvianolic acid B and ginsenoside Rg1 combination against acute ischemic stroke in rats","volume":"32","author":"Fu","year":"2021","journal-title":"Neuroreport"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.128618_bb0140","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1161\/01.STR.0000141681.06735.9b","article-title":"Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume","volume":"35","author":"Vendrame","year":"2004","journal-title":"Stroke"},{"issue":"15","key":"10.1016\/j.ijbiomac.2023.128618_bb0145","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1111\/bph.13178","article-title":"A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury","volume":"172","author":"Li","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"06","key":"10.1016\/j.ijbiomac.2023.128618_bb0150","first-page":"561","article-title":"Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro","volume":"46","author":"Korninger","year":"1981","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0155","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12975-018-0644-9","article-title":"PAI-1 but not PAI-2 gene deficiency attenuates ischemic brain injury after experimental stroke","volume":"10","author":"Griemert","year":"2019","journal-title":"Transl. Stroke Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.128618_bb0160","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/ATVBAHA.119.313775","article-title":"Drug targeting of plasminogen activator inhibitor-1 inhibits metabolic dysfunction and atherosclerosis in a murine model of metabolic syndrome","volume":"40","author":"Khoukaz","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"25","key":"10.1016\/j.ijbiomac.2023.128618_bb0165","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198512193132501","article-title":"Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction","volume":"313","author":"Hamsten","year":"1985","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.128618_bb0170","first-page":"113","article-title":"Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1, Blood","volume":"116","author":"Meltzer","year":"2010","journal-title":"The Journal of the American Society of Hematology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.128618_bb0175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2013.04.003","article-title":"TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells","volume":"132","author":"Yasui","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.622473","article-title":"Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition","volume":"7","author":"Sillen","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"14","key":"10.1016\/j.ijbiomac.2023.128618_bb0185","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1021\/jm049766q","article-title":"Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization","volume":"47","author":"Elokdah","year":"2004","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.128618_bb0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/jpet.105.084129","article-title":"Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy) phenyl]-1H-indol-3-yl}(oxo) acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis","volume":"314","author":"Hennan","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.128618_bb0195","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1161\/01.CIR.91.4.1175","article-title":"Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1\u2013neutralizing monoclonal antibody","volume":"91","author":"Biemond","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110528","article-title":"Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis","volume":"130","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2023.128618_bb0205","first-page":"1","article-title":"Compartmentalized actions of the plasminogen activator inhibitors, PAI-1 and Nsp, in ischemic stroke","author":"Torrente","year":"2022","journal-title":"Transl. Stroke Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.128618_bb0210","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1074\/jbc.RA118.004885","article-title":"Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate","volume":"294","author":"Reinke","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.128618_bb0215","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1074\/jbc.M110.204537","article-title":"Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1","volume":"286","author":"Lin","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.128618_bb0220","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/jcmm.12875","article-title":"A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase","volume":"20","author":"Gong","year":"2016","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.128618_bb0225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.STR.29.1.4","article-title":"PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke","volume":"29","author":"del Zoppo","year":"1998","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.ijbiomac.2023.128618_bb0230","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023055174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023055174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:10:31Z","timestamp":1758885031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813023055174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":46,"alternative-id":["S0141813023055174"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.128618","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.128618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128618"}}